SNMMI joins new consortium to harmonize radiopharmaceutical dosimetry

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has joined the new Precision Dosimetry Imaging Biomarker (PDIB) consortium.

Through its involvement, SNMMI will contribute to a "harmonized" framework for implementing radiopharmaceutical therapy (RPT) dosimetry in the clinic. The Foundation for the National Institutes of Health (FNIH) will lead the three-year, $4.9 million public-private partnership and project; SNMMI is one of 32 public-sector, academic, and industry partners involved.

“By working collaboratively to standardize and improve dosimetry, this initiative has the potential to maximize therapeutic benefits, ultimately improving outcomes and quality of life for cancer patients worldwide,” said SNMMI President Cathy Sue Cutler, PhD. Methods for measuring RPT radiation can vary across administration centers, and PDIB will leverage current imaging techniques to track RPT dose and location, helping clinicians optimize treatment, according to SNMMI.

The FNIH said the PDIB project will:

• Establish radiation measurement procedures and an international academic network of standards laboratories to provide accurate quantification of radiation doses.
• Optimize and standardize calibration methods to ensure accuracy and consistency of image-derived activity measurements.
• Develop and validate reproducible RPT dosimetry protocols to enable reliable, harmonized measurements between sites and clinicians.